Recherche
Résultats 1-10 de 12
-
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Journal of clinical oncology, 2017, 35, 2473Article dans une revue scientifique -
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
American journal of hematology, 2016, 91, 179-184Article dans une revue scientifique -
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Leukemia, 2018Article dans une revue scientifique -
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular b-cell lymphoma (galen): a multicentre, single-arm, phase 2 study
The Lancet. Haematology, 08-07-2019Article dans une revue scientifique -
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
The New England journal of medicine, 2018, 379, 934-947Article dans une revue scientifique -
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study
The Lancet. Haematology, 2018, 5, E403-E410Article dans une revue scientifique -
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Journal of clinical oncology, 2017, 35, 1905-+Article dans une revue scientifique -
Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment
Bulletin du cancer, 2017, 104, 221-231Article dans une revue scientifique -
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
Blood, 2017, 129, 2616-2623Article dans une revue scientifique -
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA
Ann. Oncol., 2016, 27, 1349-1350Article dans une revue scientifique